Document:

Exhibit 10.2

 

DEED OF IRREVOCABLE UNDERTAKING – DIRECTOR

 

		To:	Eagle Pharmaceuticals, Inc. (“Eagle”)

 

50 Tice Blvd, Suite 315

 

Woodcliff Lake

 

NJ 07677

 

USA

 

		From:	[Name of director]

 

[Address]

 

______ March 2022

 

Dear Sirs and Madams,

 

Proposed acquisition of the entire issued and
to be issued share capital of Acacia Pharma Group plc (the “Company”) by Eagle

 

		1.	I understand that Eagle intends to make an offer to acquire the entire issued and to be issued share capital
of the Company (the “Acquisition”) which is proposed to be implemented by way of a scheme of arrangement under Part 26
of the UK Companies Act 2006 (the “CA 2006”) (including any new, increased, renewed or revised scheme of arrangement,
the “Scheme”) substantially on the terms and conditions set out in the draft co-operation agreement appended to this
deed at Appendix II, to be entered into between Eagle and the Company on or around the date of this deed, with such amendments as may
be agreed in writing between Eagle and the Company (the “Co-operation Agreement”).

 

		2.	Terms not defined in this deed shall bear the same meaning as in the Co-operation Agreement.

 

		3.	This deed sets out the terms and conditions on which I will exercise, or procure the exercise of, the
votes attaching to the securities in the capital of the Company in which I have an interest (as set out in Appendix I) in favour of the
Scheme at any relevant meetings of the members of the Company.

 

		4.	In consideration of Eagle signing the Co-operation Agreement and agreeing to be bound by the Scheme in
the event the Scheme becomes effective, I, by reason of being a shareholder and/or option holder of the Company, irrevocably and
unconditionally warrant, undertake to and confirm and agree with Eagle on the following terms.

 

    1

     

    

 

		A.	Shareholdings

 

		5.	I irrevocably and unconditionally undertake and warrant to Eagle that:

 

		5.1.	I am the sole beneficial owner of and, unless otherwise specified in Appendix I hereto, I am also
the sole registered holder of (or am otherwise able to control the exercise of all rights, including voting rights and the ability to
procure the transfer of, attaching to) the number of ordinary shares of £0.02 each in the capital of the Company (the “Company
Securities”, which expression shall include any other shares or securities in the Company acquired by me or issued or transferred
to me after the date hereof, including those attributable to or derived from any such shares or as a result of the exercise of any options
or Awards (as defined below) which I may hold, and which I have become the registered holder, beneficial owner or otherwise interested
in) set forth in Appendix I hereto in accordance with and as further detailed in paragraph 6.2;

 

		5.2.	if I have been granted options and awards over shares in the capital of the Company under the Company’s
share scheme(s) or equity incentive schemes, their details are as set forth in Appendix I hereto (the “Awards”)
and the Awards are still subsisting and I am beneficially entitled to the Awards;

 

		5.3.	I am not (and none of my affiliates are) interested in any shares, options, warrants, short positions
or other rights or securities of the Company other than those of which details are set forth in Appendix I hereto;

 

		5.4.	I have all relevant power and authority and the right (free from any legal or other restrictions) to enter
into this deed, to perform the obligations contained in this deed in accordance with its terms and I have full power and authority to
(where relevant) exercise any aforementioned options or Awards and vote and sell, or procure the sale of, the Company Securities with
full title guarantee, free from any lien, charge, option, equity encumbrance, rights of pre-emption, legal or other restrictions, together
with all rights attaching to or enjoyed by them, including, but not limited to, any voting rights, the right to receive and retain in
full all dividends and other distributions (if any) announced, declared, made or paid on or after the date of this deed as envisaged by
the terms of the Acquisition;

 

		5.5.	the information set out in Appendix I regarding the Company Securities is complete and accurate and, other
than as set out in Appendix I, I do not have any interest in any securities or shares of the Company or any rights to subscribe for,
purchase or otherwise acquire any securities or shares of the Company;

 

		5.6.	I have full power and authority to enter into this deed and to perform the obligations under it in respect
of the Company Securities; and

 

		5.7.	I will not take any action which would cause me to cease to have all relevant power and authority and
right to enter into and perform the obligations in this deed in accordance with their terms.

 

    2

     

    

 

		B.	Dealings in the Company Securities

 

		6.	I irrevocably and unconditionally undertake and warrant to Eagle that:

 

		6.1.	I shall not:

 

		6.1.1.	exercise any voting rights attaching to the Company Securities in such manner as to frustrate or otherwise
hinder the Scheme and take any action which might result in any condition of the Scheme not being satisfied;

 

		6.1.2.	sell, transfer, loan, charge, pledge, encumber, grant any option or other right over or otherwise deal
or dispose of, or permit the sale, transfer, loan, charging, pledging, encumbering, granting of any option or other right over or other
dealing or disposal of any of the Company Securities or interest in the Company Securities other than pursuant to the Scheme, provided
that nothing in this paragraph shall prevent me from charging, pledging or encumbering any of my Company Securities (having provided at
least five days’ written notice to Eagle in advance of such charging, pledging or encumbering) if the terms on which the Company
Securities are charged, pledged or encumbered allow me to exercise the voting rights attaching to the Company Securities and provided
further that, subject to paragraph 6.2, nothing in this paragraph shall prevent me from selling, transferring, charging, pledging or encumbering,
granting of any option or other right over or other dealing or disposal of any of the Company Securities or interest in the Company Securities:

 

		6.1.2.1.	where the Company Securities disposed have been acquired by me as result of the grant, vesting or exercise
of options and such action is undertaken to cover my liability for tax and employee National Insurance or other social security contributions
arising as a result of or otherwise in respect of the grant, vesting or exercise of any options; and/or

 

		6.1.2.2.	where such action: (a) involves the sale or transfer of Company Securities to one or more of my close
relatives and/or related trusts; or (b) in any other case, is undertaken as part of my bona fide tax planning, in each case with
the prior written consent of Eagle, not to be unreasonably withheld, conditioned or delayed;

 

		6.1.3.	accept or give any undertaking (whether conditional or unconditional) or letter of intent to accept any
other offer (whether such offer is to be implemented by way of a takeover offer, scheme of arrangement, merger or other business combination
of any nature whatsoever) made or proposed to be made in respect of the issued and to be issued share capital of the Company by any other
person other than Eagle or its affiliates;

 

    3

     

    

 

		6.1.4.	(other than pursuant to the Scheme) enter into any agreement or arrangement or incur any obligation with
any person (other than Eagle or its affiliates):

 

		6.1.4.1.	in relation to, or operating by reference to, shares or other securities of the Company or any options
over such shares or securities;

 

		6.1.4.2.	to do all or any of the acts referred to in sub-paragraphs 6.1.2 and/or 6.1.3 above in relation to, or
operating by reference to, the Company Securities; or

 

		6.1.4.3.	which, in relation to the Company Securities, would or might restrict or impede my voting in favour of
the Scheme or my ability to comply with the terms of this deed,

 

and, for the avoidance of doubt, references
in paragraphs 6.1.3 and/or 6.1.4 to any acceptance of an offer or any agreement, arrangement or obligation includes any acceptance of
an offer or agreement, arrangement or obligation whether or not legally binding or subject to any condition or which is to take effect
upon or following the closing (or, if applicable, becoming effective) or lapsing of the Scheme or upon or following this deed ceasing
to be binding or upon or following any other event.

 

		6.2.	Without limitation to the restrictions in paragraph 6.1, in the event that after the date of this deed, I
acquire or purchase any shares, securities or interests in securities of the Company or rights therein (including, without limitation,
through the exercise of options, Awards or acceleration of any conditional awards under any share scheme or equity incentive scheme implemented
by the Company) or otherwise become the registered holder or beneficial owner of further shares, securities or interests in securities
of the Company or in respect of which I become entitled to exercise all rights or interests, such shares, securities, interests or rights
shall be deemed to be included in the definition of “Company Securities” and the undertakings and agreements as set
out in this deed in relation to such Company Securities shall be performed as soon as reasonably practicable but by no later than one
Business Day following the earlier of: (i) the date of allotment of such Company Securities; (ii) the registration of the relevant
securities in my name; or (iii) when I become the beneficial owner or are otherwise entitled to exercise all rights in respect of
such securities (as applicable).

 

		C.	Scheme

 

		7.	I irrevocably agree and undertake:

 

		7.1.	that a confirmation of this undertaking may be included in the Scheme Document (as defined below);

 

		7.2.	to attend (either in person or by proxy) any meeting of the Company’s shareholders convened by order
of the High Court of Justice in England and Wales (the “Court”) (including any adjournments or postponements thereof)
pursuant to section 896 of the CA 2006 to consider and approve the Scheme (the "Court Meeting") and any general or class
meeting of the Company’s shareholders (including any adjournments or postponements thereof) convened by the Company in order to
consider and approve measures required to implement the Scheme (the "General Meeting"); and

 

    4

     

    

 

		7.3.	to use reasonable endeavours to procure the convening of the Court Meeting and/or the General Meeting
as may be necessary to pass the resolutions required to implement or effect the Scheme.

 

		8.	Without limitation and in addition to the general voting undertakings granted in paragraph 10 below, I
shall exercise (or, where applicable, procure the exercise of) all voting rights (whether on a show of hands or a poll and whether in
person or by proxy) attaching to the Company Securities:

 

		8.1.	at the Court Meeting, in favour of the resolutions proposed at the Court Meeting to vote to approve, implement
or effect the Scheme; and

 

		8.2.	at the General Meeting, in favour of the resolutions proposed at the General Meeting to approve, implement
or effect the Scheme and all related matters (including any proposed amendment to the articles of association of the Company).

 

		9.	In particular and without limiting paragraph 7 above, as soon as possible and in any event not later than
1:00 p.m. on the date falling five Business Days after the deemed date of receipt of: (a) the formal document containing the
notice of the Court Meeting and the General Meeting (the “Scheme Document”); and (b) the accompanying forms of
proxy, I shall in respect of the Company Securities:

 

		9.1.	execute and deliver to the Company (in accordance with the delivery instructions contained therein) (or
procure the execution and delivery to the Company of) such forms of proxy in accordance with the instructions printed on such forms of
proxy; and

 

		9.2.	in respect of any of the Company Securities in uncertificated form, take (or procure the taking of) any
action to make a valid proxy appointment and give valid proxy instructions,

 

to vote in favour of each of the resolutions
to be proposed at the Court Meeting and/or the General Meeting and, unless instructed to do so by Eagle, shall not thereafter revoke such
forms of proxy or proxy appointments and proxy instructions, either in writing or by attendance at any meeting or otherwise.

 

		D.	Voting – general

 

		10.	In each case save as specifically set out in paragraph ‎8:

 

		10.1.	I shall exercise (or procure the exercise of) the voting rights attached to the Company Securities on
any resolution which would assist the implementation of the Scheme; and

 

		10.2.	save as agreed in writing between Eagle and the Company, I shall exercise (or procure the exercise
of) the voting rights attached to the Company Securities against any resolution:

 

		10.2.1.	to the effect that the text or terms of the resolutions to be proposed at the General Meeting to approve
the Scheme and all related matters be amended;

 

		10.2.2.	to adjourn the General Meeting; and

 

    5

     

    

 

		10.2.3.	that purports to approve or give effect to (and I will not be bound or agree to be bound by) a proposal
by a person other than Eagle or its affiliates to acquire any shares or securities of the Company in issue or to be issued.

 

		E.	Power of attorney

 

		11.	In order to secure the performance of my obligations contained in this deed (and only to the extent I
have failed to comply with such obligations), I hereby on behalf of myself, and shall procure that the registered holder of the Company
Securities (if different) shall, appoint Eagle and each director of Eagle severally as my attorney in my name or otherwise and on my behalf
to: (a) sign, execute and deliver: (i) a form or forms of proxy; (ii) all other documents related to or in connection with
the Scheme; and (iii) all other documents required to be delivered by me under this deed, which are (in each case) to be signed by
me; and (b) comply with the terms of the Scheme Document and fulfil my obligations in relation to any above document or under this
deed if by the fifth Business Day after the date of deemed receipt of the Scheme Document I have not complied with any provision of this
deed within the specified period.

 

		12.	I agree that the power of attorney given in paragraph 11 is given by way of security and is irrevocable
in accordance with section 4 of the Powers of Attorney Act 1971 until this deed lapses or is terminated, or (if earlier) the Scheme becomes
effective.

 

		F.	Announcements, information and documentation

 

		13.	I agree to comply, and to use reasonable endeavours to procure that the Company complies, with the terms
of the announcements and confidentiality provisions set out in clause 20 (Announcements) of the Co-operation Agreement which are
incorporated into this deed by reference and shall apply mutatis mutandis on and from the date of this deed.

 

		14.	I consent to the inclusion of references to me and the particulars and provisions of this deed in the
Co-operation Agreement, the Scheme Document and any document issued or published in connection with the Acquisition (in any manner of
medium) and/or that is required by any other legal or regulatory requirements.

 

		15.	I irrevocably and unconditionally shall:

 

		15.1.	promptly give Eagle all information and any assistance as Eagle may reasonably require for the preparation
of any such announcement or document in order to comply with the requirements of the Court, the CA 2006 and any other legal or regulatory
requirement or body (but will not be required to take responsibility for any information or other matters other than factual information
relating solely to myself); and

 

		15.2.	immediately notify Eagle in writing of any material change in the accuracy or impact of any information
previously given to Eagle or in the event of any breach of the undertakings, representations or warranties set out herein.

 

    6

     

    

 

		G.	Termination

 

		16.	The undertakings, warranties, consents, waivers, agreements and obligations in this deed will only lapse
and cease to have effect:

 

		16.1.	if the Scheme does not become effective, lapses or is withdrawn without becoming or being declared unconditional
in accordance with its terms; or

 

		16.2.	the Scheme lapses or is withdrawn or otherwise becomes incapable of becoming effective or has not become
effective on or before the date falling six months after the date of this deed (or such later date as Eagle and the Company agree in writing
and that the Court, if required, approves).

 

		H.	General

 

		17.	For the avoidance of doubt, nothing in this deed shall oblige Eagle to effect the Acquisition.

 

		18.	Any date, time or period referred to in this deed shall be of the essence except to the extent to which
Eagle and I agree in writing to vary any date, time or period, in which event the varied date, time or period shall be of the essence.

 

		19.	This deed shall be binding on my successors and assignees. I acknowledge and agree that I may not assign
or otherwise dispose of any rights under this deed, at law or in equity, including by way of declaration of trust. Any purported assignment
in breach of this paragraph 19 shall be void and confer no rights on the purported assignee.

 

		20.	Eagle may assign all or any part of the benefit of, or its rights or benefits under, this deed to:

 

		20.1.	any member of Eagle’s group of companies (the “Eagle Group”) (or by any such
member of the Eagle Group to or in favour of any other member of the Eagle Group) provided that if such assignee subsequently ceases to
be a member of the Eagle Group, Eagle shall procure that, prior to its ceasing to be so, such assignee reassigns to Eagle or (upon giving
prior written notice to me) to another member of the Eagle Group so much of the rights and benefits under this deed as have been assigned
to it; and

 

		20.2.	by way of security and/or charge all or any of its rights under this deed for the benefit of:

 

		20.2.1.	any financial institution or other person lending money or making other credit facilities available to
any member of the Eagle Group (including the holders of any debt securities);

 

		20.2.2.	any counterparty to a derivative transaction entered into by a member of the Eagle Group; or

 

		20.2.3.	any facility or security agent, security trustee, arranger of finance, receiver or person fulfilling a
similar or related role, as security for the obligations owed by any member of the Eagle Group to such person, and any such beneficiary
of security may assign all or any of those rights.

 

    7

     

    

 

		21.	If an assignment is made in accordance with paragraph ‎20:

 

		21.1.	my liability to any such assignee shall not be greater than my liability to Eagle if that assignment had
not occurred; and

 

		21.2.	references to Eagle (other than in this paragraph 21.2) shall be construed as references to the holder,
at any relevant time, of Eagle's rights under this deed.

 

		22.	Except to the extent otherwise specified, my obligations set out in this deed are unconditional and irrevocable.

 

		23.	With regard to any Company Securities not registered in my name, the confirmations, warranties and undertakings
contained in this deed are given by me on behalf of the registered holder(s) of such Company Securities and I undertake to ensure
the compliance by such person(s) with those confirmations, warranties and undertakings.

 

		24.	In this deed:

 

		24.1.	all references to time are to London time; and

 

		24.2.	a person will be treated as having an interest in securities if:

 

		24.2.1.	such person owns such securities;

 

		24.2.2.	such person has the right (whether conditional or absolute) to exercise or direct the exercise of the
voting rights attaching to such securities or has general control of such securities;

 

		24.2.3.	by virtue of any agreement to purchase, option or derivative, such person:

 

		24.2.3.1.	has the right or option to call for the delivery of such securities; or

 

		24.2.3.2.	is under an obligation to take delivery of such securities, whether the right, option or obligation is
conditional or absolute and whether it is in the money or otherwise; or

 

		24.2.4.	such person is a party to any derivative whose value is determined by reference to their price and which
results, or may result, in them having a long position in such securities.

 

		25.	Each of Eagle, any member of the Eagle Group and the Company may, under the Contracts (Rights of Third
Parties) Act 1999 or otherwise, enforce the terms of this deed.

 

		26.	Save as provided in paragraph 25, a person who is not party to this deed has no right under the Contracts
(Rights of Third Parties) Act 1999 to enforce any term of this deed.

 

		27.	The invalidity, illegality or unenforceability of any provision of this deed shall not affect the continuation
in force of the remainder of this deed.

 

    8

     

    

 

		28.	This deed and the agreements referred to herein contain the whole agreement between Eagle and me relating
to the subject matter of this deed at the date hereof to the exclusion of any terms implied by law which may be excluded by contract.
I acknowledge that I have not been induced to sign this deed by any representation, warranty or undertaking not expressly incorporated
into it.

 

		29.	This deed has been entered into in my capacity as a shareholder only and without prejudice to any statutory
or fiduciary obligations I may have in my capacity as a director of the Company.

 

		30.	I agree that damages would not be an adequate remedy for breach by me of any of my obligations under or
pursuant to this deed and accordingly, without prejudice to any other rights or remedies that Eagle may have, Eagle shall be entitled
to the remedies of specific performance, injunction or other equitable relief for any threatened or actual breach of any such obligations
and no proof of special damages shall be necessary for the enforcement by Eagle of its rights.

 

		31.	I agree that this deed (and any dispute, controversy, proceedings or claim of any nature arising out of
or in connection with it, including non-contractual disputes and claims) shall be governed and construed in accordance with English law.

 

		32.	I irrevocably agree to submit to the exclusive jurisdiction of the courts of England to settle any claim,
legal action, proceeding, dispute or matter of difference (including non-contractual claims, disputes or differences) which may arise
out of or in connection with this deed or its subject matter (including a dispute regarding the existence, validity, formation, effect,
interpretation, performance or termination of this deed) and that accordingly any proceedings be brought in such courts.

 

[Remainder
of page intentionally left blank]

 

    9

     

    

 

IN WITNESS whereof this document has been
duly executed and delivered as a deed on the date above mentioned.

 

	SIGNED as a DEED	)	 	 
	 	 	 	 
	By [●]	)	 	 
	 	 	 	 
	in the presence of:	)	 	 

 

	Witness’s signature:	 	 
	 	 	 
	Witness’s name:	 	 
	 	 	 
	Witness’s address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Witness’s occupation:	 	 

 

    10

     

    

 

APPENDIX I

 

INTERESTS IN THE COMPANY

 

		1.	Interests in the Company

 

My “interests” (as defined in Part 22
of the CA 2006) in the securities (including securities convertible thereto, rights to subscribe therefor, options (including traded options)
in respect thereof and derivatives referenced thereto) of the Company on the date hereof are as stated below:

 

	Registered holder* and address	Beneficial owner* and address	Number of ordinary shares of 

 £0.02 each in the capital of the 

Company
	 	 	 
	 	 	 

 

		2.	Options

 

The details of my options to subscribe for securities
in the capital of the Company on or after the date hereof are as stated below:

 

	Registered holder* 

and address	Beneficial owner*

 and address	Number of

 options	Exercise price

 and period	
    Date of grant

    (DD/MM/YY)

	 	 	 	 	 
	 	 	 	 	 

 

Explanatory notes:

 

		i.	* Where more than one, indicate number of shares attributable to each.

 

		ii.	Where no interests are held, please complete table with “Nil” entries.

 

    11

     

    

 

APPENDIX II

 

CO-OPERATION AGREEMENT

 

    12Exhibit 10.3

 

LOCK-UP AGREEMENT

 

This lock-up agreement, dated
March 27, 2022 (this “Agreement”), by and between the undersigned holder (the “Holder”) and
Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Buyer”), is being executed and delivered in connection
with the co-operation agreement, dated as of March 27, 2022 (the “Co-operation Agreement”), by and among the
Buyer and Acacia Pharma Group PLC, a public company limited by shares, incorporated in England and Wales whose registered office is at
The Officers’ Mess Royston Road, Duxford, Cambridge, England, CB22 4QH with company number 09759376 (the “Company”),
pursuant to which the Buyer intends to acquire the entire issued and to be issued share capital of the Company (the “Acquisition”)
which is proposed to be implemented by way of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the “Scheme”),
with the Company continuing as a wholly-owned subsidiary of the Buyer, pursuant to the terms and subject to the conditions provided for
in the Co-operation Agreement and the Scheme (as defined in the Co-operation Agreement) (the “Transaction” and the
date the Transaction is consummated, the “Effective Date”).

 

WHEREAS, the Holder is a shareholder
of the Company immediately prior to the consummation of the Transaction and, as such, will benefit from the transactions contemplated
by the Co-operation Agreement and the Scheme; and

 

WHEREAS, the execution and
delivery of this Agreement by the Holder is a condition to the Holder’s receipt of a portion of the consideration provided for in
connection with the Scheme, a portion of which may be paid in New Eagle Shares (as defined in the Co-operation Agreement).

 

NOW, THEREFORE, for good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged and intending to be legally bound, the parties hereto
agree as follows:

 

		1.	Lock-Up.

 

		(a)	The Holder shall not, other than with the consent of the Buyer’s board of directors, offer, sell,
lease, contract to sell, pledge, assign, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly,
the shares of common stock, par value $0.001 per share, of the Buyer (“Buyer Common Stock”) issued in the Holder’s
favor by the Buyer within 14 days of the Effective Date in connection with the Scheme (each such issued shares of Buyer Common Stock,
as applicable, the “Locked-Up Shares”), for twelve (12) months following the effective date of issuance of Buyer Common
Stock in favor of the Holder (such twelve (12)-month period, the “Lock-Up Period”).

 

    1 

     

    

 

		(b)	Notwithstanding the provisions of Section 1(a), during the Lock-Up Period, the Holder may
transfer all or a portion of the Locked-Up Shares: (i) as a bona fide gift or gifts, provided that the donee or donees thereof agree
in writing, in form and substance reasonably satisfactory to the Buyer, to be bound by the restrictions set forth in this Section 1,
(ii) to the Holder’s affiliates (including, if applicable, commonly controlled or managed investment funds (or to any member,
shareholder or limited or general partner of any such investment funds)) who execute a written joinder to this Agreement; provided
that the Holder’s affiliates agree in writing, in form and substance reasonably satisfactory to the Buyer, to be bound by the restrictions
set forth in this Section 1, or (iii) pursuant to any transaction approved or recommended by the Buyer’s board
of directors, including any tender offer, stock split, share subdivision or consolidation, bonus issue, dividend or combination, or any
reclassification, recapitalization, merger, amalgamation, consolidation, exchange or other similar reorganization. For purposes hereof,
 “affiliate” shall mean, as applied to any entity, any other entity directly or indirectly controlling, controlled by,
or under direct or indirect common control with, such entity, or any director, manager or officer of such entity (for purposes hereof,
 “control” (including, with correlative meanings, the terms “controlling,” “controlled by”
and “under common control with”), as applied to any entity, means the possession, directly or indirectly, of the power
to direct or cause the direction of the management and policies of such entity, whether through the ownership of voting securities, by
contract or otherwise).

 

		(c)	The Holder, for the duration of the Lock-Up Period, consents to the entry of stop transfer instructions
with the Buyer’s transfer agent and registrar against the transfer of the Locked-Up Shares except in compliance with the restrictions
set forth in this Section 1.

 

		(d)	The Holder acknowledges that the Locked-Up Shares bear the following legend evidencing the lock-up restrictions
set forth in this Section 1 (which legend the Buyer shall cause to be removed promptly upon the end of the applicable Lock-Up
Period):

 

“THE SHARES OF STOCK REPRESENTED
BY THIS CERTIFICATE OR BOOK ENTRY POSITION ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR TWELVE MONTHS FOLLOWING THE EFFECTIVE DATE OF THEIR
ISSUANCE PURSUANT TO A LOCK-UP AGREEMENT, AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY THE HOLDER PRIOR TO THE EXPIRATION OF SUCH
PERIOD WITHOUT THE CONSENT OF THE COMPANY. A COPY OF THE LOCK-UP AGREEMENT IS ON FILE AT THE PRINCIPAL OFFICES OF THE COMPANY AND MAY BE
OBTAINED UPON WRITTEN REQUEST OF THE SECRETARY OF THE CORPORATION.”

 

		2.	Representations and Warranties. The Holder hereby represents and warrants to the Buyer that the
Holder has all requisite power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate
the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by the Holder and is a legal, valid
and binding obligation of the Holder, enforceable against it in accordance with its terms, except to the extent that enforceability thereof
may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium and other similar laws affecting the enforcement
of creditors’ rights generally and by general principles of equity.

 

    2 

     

    

 

		3.	Binding Effect. This Agreement shall be binding upon the parties hereto and each of their heirs,
beneficiaries, legal representatives, successors and assigns, as applicable.

 

		4.	Governing Law. This Agreement (including any claim or controversy arising out of or relating to
this Agreement) shall be governed by and construed in accordance with the Laws of the State of Delaware, without regard to conflict of
law principles that would result in the application of any Law other than the Laws of the State of Delaware.

 

		5.	Severability. If any provision of this Agreement is held invalid or unenforceable by any court
of competent jurisdiction, the other provisions of this Agreement shall remain in full force and effect. Any provision of this Agreement
held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.
The parties hereto further agree to replace such invalid or unenforceable provision of this Agreement with a valid and enforceable provision
that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable provision.

 

		6.	Counterparts. This Agreement may be executed in a number of identical counterparts (including by
PDF or other electronic transmission), all of which shall constitute one agreement.

 

* * * * *

 

    3 

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed
and delivered this Agreement as of the date first written above.

 

	 	HOLDER:
	 	 
	 	COSMO TECHNOLOGIES LIMITED
	 	 
	 	 
	 	By:	/s/ Niall Donnelly 
	 	Name:	 Niall Donnelly
	 	Title:	CFO

 

[Signature page to lock-up agreement]

 

    

     

    

 

	 	BUYER:
	 	 
	 	EAGLE PHARMACEUTICALS, INC.
	 	 
	 	 
	 	By:	/s/ Scott Tarriff
	 	Name: 	Scott Tarriff
	 	Title:	Director

 

[Signature page to lock-up agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]